#USA #Minneapolis #Bio-Techne #Biomarkers #Ella

Bio-Techne Unveils Simple Plex Ultra-Sensitive Assays on Ella Platform

Bio-Techne Corporation, a leader in life science tools and diagnostic products, has made an exciting development in the field of neurological research with the launch of their Simple Plex Ultra-Sensitive Assays on the Ella automated platform. This cutting-edge technology allows for the detection of neurological biomarkers at femtogram levels, addressing a long-standing challenge in diagnosing neurodegenerative diseases.

Breaking Down the Challenge of Neurodegenerative Diseases

Detecting early signs of neurodegenerative conditions like Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS) has historically been complicated due to the low concentration of specific biomarkers in biofluids like blood. Early diagnosis is crucial for effective treatment, yet conventional methods often miss these low-abundance proteins.

The newly launched Simple Plex Ultra-Sensitive Assays make a significant leap forward, offering enhanced analytical sensitivity. Key biomarkers can now be reliably quantified, including neurofilament light chain (NFL), glial fibrillary acidic protein (GFAP), phosphorylated tau (pTau 217), and amyloid beta (aa1-42). These innovations empower researchers to observe subtle biological changes often overlooked in earlier studies, helping to accelerate understanding of disease onset, progression, and response to treatments.

Improving Research with Enhanced Performance

This advancement is built upon the Ella platform's established reputation, which has influenced over 200 peer-reviewed articles relating to neurology and translational research. Will Geist, President of Bio-Techne's Protein Sciences Segment, emphasizes that the combination of femtogram-level detection with a fully automated microfluidic platform enables the precise quantification of low-abundance biomarkers, which are usually undetectable using traditional immunoassay techniques.

Moreover, the automated workflow of Ella reduces manual intervention, minimizing variability and speeding up the assay process to under three hours for results—an impressive turnaround that supports high-throughput studies focused on understanding disease trajectories and uncovering new therapeutic targets.

Strengthening Leadership in Immunoassays

The launch of these ultra-sensitive assays further cements Bio-Techne's position as a leader in the immunoassay space, merging advanced proteomic assays with automation to heighten reproducibility, throughput, and data quality. Ella has been referenced in over 1,000 peer-reviewed publications, which underscores its significant role in advancing neuroscience research and precision medicine.

The Simple Plex assays are expressly designed for research use only, inviting academic and clinical researchers to explore the new possibilities they present in the ongoing fight against neurodegenerative diseases.

For additional details and to explore Bio-Techne's comprehensive portfolio, visit Bio-Techne's website.

Bio-Techne Corporation, listed on NASDAQ under the ticker symbol TECH, continues to thrive as an innovator in the life sciences sector, generating more than $1.2 billion in net sales for fiscal year 2025 and employing around 3,100 professionals globally.

Conclusion

Bio-Techne's launching of the Simple Plex Ultra-Sensitive Assays on the Ella platform is more than just a product release; it represents a pivotal advancement for neuroscience research, enhancing the ability to detect and interpret early markers of neurodegeneration and ultimately paving the way for improved patient outcomes. As research continues to evolve, tools like these will be essential for shedding light on the complexities of neurological disorders.